Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine ; volume:31 ; number:6 ; day:14 ; month:8 ; year:2024 ; pages:1037-1045 ; date:11.2024
Breast cancer ; 31, Heft 6 (14.8.2024), 1037-1045, 11.2024
- Urheber
-
Kitadai, Rui
Shimoi, Tatsunori
Yazaki, Shu
Okuma, Hitomi Sumiyoshi
Hoshino, Mai
Ito, Munehiro
Saito, Ayumi
Kita, Shosuke
Kojima, Yuki
Nishikawa, Tadaaki
Sudo, Kazuki
Noguchi, Emi
Fujiwara, Yasuhiro
Yoshida, Masayuki
Yonemori, Kan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12282-024-01617-y
- URN
-
urn:nbn:de:101:1-2501072122185.108373085512
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kitadai, Rui
- Shimoi, Tatsunori
- Yazaki, Shu
- Okuma, Hitomi Sumiyoshi
- Hoshino, Mai
- Ito, Munehiro
- Saito, Ayumi
- Kita, Shosuke
- Kojima, Yuki
- Nishikawa, Tadaaki
- Sudo, Kazuki
- Noguchi, Emi
- Fujiwara, Yasuhiro
- Yoshida, Masayuki
- Yonemori, Kan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
Clinicopathological features and prognosis of patients with HER2-low breast cancer
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study